<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00569153</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-700_201</org_study_id>
    <secondary_id>TAK-700-201</secondary_id>
    <nct_id>NCT00569153</nct_id>
  </id_info>
  <brief_title>Safety Study of TAK-700 in Subjects With Prostate Cancer.</brief_title>
  <acronym>TAK-700</acronym>
  <official_title>A Phase 1/2, Open-Label, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Millennium Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of TAK-700 in patients&#xD;
      with asymptomatic metastatic, androgen independent prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of TAK-700 by evaluating adverse events, vital signs, physical examination findings, concomitant medications and laboratory tests.</measure>
    <time_frame>Cycle 1: Weeks 1, 2, 3 and 4, then every 4 weeks thereafter.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy and pharmacokinetics (PSA response and/or objective disease response)</measure>
    <time_frame>Cycle 1: Weeks 1, 2, 3 and 4, then every 4 weeks thereafter.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm 1 (TAK-700)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 (TAK-700 at 400 mg &amp; 5 mg prednisone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 (TAK-700 at 600 mg &amp; 5 mg prednisone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4 (TAK-700 at 600 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-700</intervention_name>
    <description>Phase 1 portion of study:&#xD;
TAK-700 dose escalation. Tablets administered orally, twice daily until disease progression or occurrence of an unacceptable adverse event.&#xD;
Phase 2 portion of study:&#xD;
Patients will receive one of 4 treatments:&#xD;
TAK-700 at 300 mg twice/day&#xD;
TAK-700 at 400 mg and 5 mg prednisone twice/day&#xD;
TAK-700 at 600 mg and 5 mg prednisone twice/day&#xD;
TAK-700 at 600 mg once/day in the morning</description>
    <arm_group_label>Arm 1 (TAK-700)</arm_group_label>
    <arm_group_label>Arm 2 (TAK-700 at 400 mg &amp; 5 mg prednisone)</arm_group_label>
    <arm_group_label>Arm 3 (TAK-700 at 600 mg &amp; 5 mg prednisone)</arm_group_label>
    <arm_group_label>Arm 4 (TAK-700 at 600 mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is male and at least 18 years of age.&#xD;
&#xD;
          -  Subject has histologically- or cytologically-confirmed prostate adenocarcinoma with&#xD;
             metastatic, progressive disease while on androgen deprivation therapy.&#xD;
&#xD;
          -  Subject has radiograph-documented (computed tomography, magnetic resonance imaging or&#xD;
             x-ray) metastatic disease.&#xD;
&#xD;
          -  Subject has undergone orchiectomy or is expected to continue receiving luteinizing&#xD;
             hormone-releasing hormone analogue therapy, and has a testosterone level of &lt;50 ng/dL&#xD;
             at screening.&#xD;
&#xD;
          -  Subject has discontinued all antiandrogen therapy (within 30 days for flutamide and&#xD;
             within 6 weeks for all others) prior to their first dose of study drug.&#xD;
&#xD;
          -  Subject has a prostate-specific antigen level â‰¥5 ng/mL.&#xD;
&#xD;
          -  Subject meets all screening laboratory values as specified in the protocol.&#xD;
&#xD;
          -  Subject has a screening ejection fraction that is above the lower limit of the&#xD;
             institutional normal range.&#xD;
&#xD;
          -  Subject has ECOG performance status of 0 to 2.&#xD;
&#xD;
          -  Subject has normal or, in the opinion of the investigator, clinically insignificant,&#xD;
             physical examination findings, ECG and chest x-ray results.&#xD;
&#xD;
          -  Subjects, even if surgically sterilized (ie, status postvasectomy), who: agree to&#xD;
             practice effective barrier contraception during the entire study treatment period and&#xD;
             for 4 months after the last dose of study drug, or agree to completely abstain from&#xD;
             heterosexual intercourse.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has known hypersensitivity to TAK-700 or related compounds.&#xD;
&#xD;
          -  Subject has received prior therapy with aminoglutethimide or ketoconazole within 30&#xD;
             days prior to the first dose of study drug.&#xD;
&#xD;
          -  Subject has received prior chemotherapy for prostate cancer.&#xD;
&#xD;
          -  Subject has received any investigational compound within 30 days prior to first dose&#xD;
             of study drug.&#xD;
&#xD;
          -  Subject has received prior herbal product known to decrease prostate-specific antigen&#xD;
             levels (eg, Saw Palmetto, PC-SPES) within 30 days prior to the first dose of study&#xD;
             drug.&#xD;
&#xD;
          -  Subject has received radiation therapy for prostate cancer within 30 days prior to&#xD;
             first dose of study drug.&#xD;
&#xD;
          -  Chronic therapy with oral or other systemically administered corticosteroids, such as&#xD;
             prednisone, within 30 days prior to Screening. Chronic therapy is defined as the use&#xD;
             of corticosteroids for more than 7 days within a 30-day period.&#xD;
&#xD;
          -  Subject has current spinal cord compression, current bilateral hydronephrosis, or&#xD;
             current bladder neck outlet obstruction.&#xD;
&#xD;
          -  Subject has a history of adrenal insufficiency.&#xD;
&#xD;
          -  Subject has a history of myocardial infarction, ischaemic symptomatic heart disease,&#xD;
             cardiac arrhythmias or thromboembolic events (eg, deep vein thrombosis, pulmonary&#xD;
             embolism, or symptomatic cerebrovascular events), or any other cardiac condition&#xD;
             (e.g., pericardial effusion restrictive cardiomyopathy) within 12 months prior to&#xD;
             first dose of study drug.&#xD;
&#xD;
          -  Subject has any symptoms which the investigator deems related to prostate cancer,&#xD;
             i.e., bone pain, pelvic pain.&#xD;
&#xD;
          -  Subject has a history of congestive heart failure (New York Heart Association Class II&#xD;
             or greater.&#xD;
&#xD;
          -  Subject has history of another malignancy other than basal cell carcinoma or state 1&#xD;
             squamous cell carcinoma of the skin, within the last 5 years.&#xD;
&#xD;
          -  Subject has uncontrolled hypertension.&#xD;
&#xD;
          -  Subject is known to have HIV infection, chronic Hepatitis B or C or any other serious&#xD;
             medical condition or psychiatric illness that might affect life expectancy or make it&#xD;
             difficult to successfully manage and follow the subject according to protocol.&#xD;
&#xD;
          -  Subject is unable to understand verbal or written English or any other language for&#xD;
             which a certified translation of the institutional review board (IRB)-approved&#xD;
             informed consent has been provided.&#xD;
&#xD;
          -  Subject is unwilling or unable to comply with the protocol or cooperate fully with the&#xD;
             investigator and site personnel.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC Westside Prostate Cancer Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Angeles Clinic and Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Medical Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Pharmacy</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evanston Hospital</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kellogg Pharmacy - Evanston Hospital</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kellogg Cancer Care Center</name>
      <address>
        <city>Glenview</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology/Oncology Associates of Central New York</name>
      <address>
        <city>East Syracuse</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taussig Cancer Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>December 4, 2007</study_first_submitted>
  <study_first_submitted_qc>December 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2007</study_first_posted>
  <disposition_first_submitted>March 4, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>March 4, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 4, 2016</disposition_first_posted>
  <last_update_submitted>March 4, 2016</last_update_submitted>
  <last_update_submitted_qc>March 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Androgen-independent prostate cancer, metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

